NTNobue Tanaka

Nobue Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nobue Tanaka has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Tetsuya Babazono

    Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    2 shared publications
  • Izumi Nyumura

    Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    1 shared publication
  • Kiwako Toya

    Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    1 shared publication
  • Ko Hanai

    Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    1 shared publication
  • Michino Takagi

    Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    1 shared publication
  • Naoshi Yoshida

    Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    1 shared publication

Latest Publications

  • Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients

    by Nobue Tanaka, Tetsuya Babazono, Michino Takagi, Naoshi Yoshida, Kiwako Toya, Izumi Nyumura, Ko Hanai, Yasuko Uchigata

    Aim: The first clinical manifestation of diabetic kidney disease is usually the development of microalbuminuria. However, recent studies have focused on diabetic patients with reduced glomerular filtration rate (GFR) without albuminuria. To evaluate the association of albuminuria and GFR with renal outcomes, we performed an observational study.Methods: A total of 3231 type 2 diabetic patients were included in this study between 2003 and 2005. There were 1249 women and the mean age was 59 ± 12 years. The renal endpoints were defined as the initiation of renal replacement therapy (RRT) or 50% reduction from the baseline of estimated GFR (eGFR).Results: At baseline, 669 (20.7%) patients had eGFR 2 and 1134 (35.1%) had albuminuria. During the mean follow‐up period of 5.9 ± 1.6 years, 107 patients initiated RRT. A 50% reduction of eGFR from the baseline value was found in 279 patients. None of the normoalbuminuric subjects with or without reduced eGFR required RRT during the observational period (P < 0.01). Compared to normoalbuminuria patients with eGFR ≥60 mL/min per 1.73 m2 at baseline, the group of normoalbuminuria patients with reduced eGFR had a 2.5‐fold risk of developing the renal endpoints, (95% confidence interval (CI): 1.0–6.3, P = 0.053). Patients with microalbuminuria with eGFR ≥60 mL/min per 1.73 m2 at baseline had a 5.0‐fold risk of developing the evaluated renal endpoints (95% CI: 2.8–8.8, P < 0.001).Conclusion: Albuminuria was a significant predictor for the evaluated renal endpoints, but the impact of eGFR is likely to be less than that of albuminuria.


  • Assessing genetic susceptibility to diabetic nephropathy

    by Nobue Tanaka, Tetsuya Babazono

    SUMMARY:  Diabetic nephropathy is a serious complication of diabetes and the leading cause of end‐stage renal disease. Studies indicate both environmental and genetic factors contribute to the development and progression of diabetic nephropathy. In particular, epidemiological evidence shows a familial clustering of nephropathy in siblings with diabetes, supporting an important role of genetic susceptibility in the pathogenesis of diabetic nephropathy.A common approach in genetic research is assessment of candidate gene polymorphisms using case‐control analysis; a number of studies have evaluated predictable candidate genes for diabetic nephropathy. In contrast, only a few studies have used a whole genome approach, such as scanning of micro‐satellite markers, in the assessment of genetic susceptibility to diabetic nephropathy. A whole genome linkage analysis using families of Pima Indians showed susceptibility loci for diabetic nephropathy on chromosome 3, 7, and 20. Another linkage analysis using discordant sib‐pairs of Caucasian families with type 1 diabetes identified a critical area on chromosome 3q. However, these results have been inconclusive and further investigation is required.Recently, a genome‐wide, case‐control analysis identifying susceptibility genes for diabetic nephropathy was performed. As a result, a single nucleotide polymorphism in exon 23 of the solute carrier family 12 (sodium‐chloride cotransporter) member 3 gene was found to be strongly associated with diabetic nephropathy. Although further assessment of this polymorphism is needed, this strategy offers great promise in the identification of genetic factors predisposing patients to diabetic nephropathy. Identification of genetic susceptibility markers may offer new hope in the diagnosis and treatment of diabetic nephropathy.